Clinical ophthalmology
Efficacy and Safety of Reproxalap 0.25% Ophthalmic Solution in Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
By Khazali MH, Alghzawi HM, Ainer MW and 6 others.
Abstract
Purpose
Dry eye disease (DED) is an ocular surface disorder characterized by tear-film instability, inflammation, and symptoms that can impair visual function and quality of life. Reproxalap is a topical reactive aldehyde species (RASP) inhibitor. This systematic review and meta-analysis assessed the efficacy and safety of reproxalap 0.25% ophthalmic solution vs vehicle in adults with DED.